Navigation Links
Echo Therapeutics Announces Significant Advance in Development of its One-Piece, Needle Free Symphony tCGM Biosensor
Date:10/29/2009

FRANKLIN, Mass., Oct. 29 /PRNewswire-FirstCall/ -- Echo Therapeutics, Inc. (OTC Bulletin Board: ECTE), a diabetes management company developing the needle-free Symphony(TM) tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring (tCGM) system and the Prelude(TM) SkinPrep System for transdermal drug delivery, announced today that it has made significant advances to the development of its needle-free Symphony tCGM biosensor. The biosensor replaces the prototype two-piece biosensor used in earlier clinical trials and is designed to offer a one-piece, cost-effective, single-use biosensor with improved performance for use by consumers and healthcare providers.

"We are extremely pleased to announce this next step in the product development work on our one-piece biosensor, a critical component of Symphony, our needle-free, continuous glucose monitoring technology," stated Patrick T. Mooney, M.D., Chairman and CEO of Echo Therapeutics. "This next generation one-piece biosensor introduces new materials and a more effective geometrical construction and replaces the prior prototype two-piece biosensor used in earlier clinical trials. We believe that this new one-piece design will significantly reduce manufacturing costs, enabling the Company to offer a low-cost product. We also believe that this design will lead to improved continuous monitoring performance since a one-piece biosensor eliminates a primary source of the motion artifact seen with the earlier prototype two-piece biosensor. We look forward to testing this new and improved biosensor in a clinical trial in the near term and confirming the performance attributes observed in internal testing."

The new one-piece biosensor utilizes new materials and effective geometry design. It is intended to be a cost-effective product that allows for advanced continuous glucose monitoring performance for consumers and healthcare providers.

About Ec
'/>"/>

SOURCE Echo Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Orexigen(R) Therapeutics Releases New Efficacy Data for Contrave(R) in Late Breaker Presentations at the 27th Annual Scientific Meeting of The Obesity Society
2. Logical Therapeutics Announces Positive Results of LT-NS001 vs. Naproxen Clinical Study
3. Horizon Therapeutics Presents Phase 3 Study Results Identifying Risk Factors for Ulcer Development Among NSAID Users
4. Inhibikase Therapeutics Discusses New Platform for Infectious Disease Pharmaceuticals at BIOCOM 2009
5. Cell Therapeutics, Inc. (CTI) to Present at 8th Annual BIO Investor Forum
6. Cell Therapeutics, Inc. Reports Outcome of Annual Meeting of Shareholders
7. Logical Therapeutics to Present Data on LT-NS001 at American College of Gastroenterology Annual Meeting
8. Talecris Biotherapeutics Receives FDA Approval for PROLASTIN(R)-C
9. Oxygen Biotherapeutics, Inc. to Webcast Shareholder Meeting
10. ZyStor Therapeutics, Inc. Cleared to Begin Clinical Trial for Targeted Protein Therapeutic for the Treatment of Pompe Disease
11. Prime Therapeutics Receives 2010 TIPPS Certification for Adherence to High Transparency Standards
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/17/2014)... , Oct. 17, 2014 UBM Medica US announces ... leading online community and information resource for neurologists and other ... and Alzheimer disease , with discussions of the latest ... 1 million Americans have Parkinson disease , more than the ... Lou Gehrig disease. Diagnosis can be difficult because ...
(Date:10/17/2014)... -- A victim of medical negligence at the hands of ... history of alcohol abuse, a physician and consumer advocates unveiled ... highlighting how Prop 46 will identify and deter physician substance ... The ad pictures a doctor drinking at a bar as ... will enact the first law in the nation requiring random ...
(Date:10/17/2014)... Inc ., reported on results of 59 glaucoma patients treated ... to 3 years with the InnFocus MicroShunt® at the 2014 ... . The Summit was held prior ... American Academy of Ophthalmology . The Company also said it ... countries by early 2015. Logo - http://photos.prnewswire.com/prnh/20141016/152617LOGO ...
Breaking Medicine Technology:Neurology Times Features Coverage of Parkinson and Alzheimer Disease 2Neurology Times Features Coverage of Parkinson and Alzheimer Disease 3Victim Of Negligence At Hands Of A Drunk Doctor, A Physician and Consumer Advocates Release New Yes on 46 TV Ad, "On Call" 2Victim Of Negligence At Hands Of A Drunk Doctor, A Physician and Consumer Advocates Release New Yes on 46 TV Ad, "On Call" 3Victim Of Negligence At Hands Of A Drunk Doctor, A Physician and Consumer Advocates Release New Yes on 46 TV Ad, "On Call" 4InnFocus Featured at the Ophthalmology Innovation Summit In Chicago 2
(Date:10/20/2014)... 2014 Based on a proprietary ... imaging assays capable of determining DNA sequence, location ... these three dimensions of high-resolution data, dGH assays ... widest range of disease-causing genetic rearrangements, including chromosomal ... genomic tools, including today’s advanced sequencing technologies. , ...
(Date:10/20/2014)... hard to imagine what it’s like to live without shoes, ... it’s a reality. And while new shoes are considered a ... barefoot on rocky terrain or sewage-lined streets just to collect ... , Buckner International's Shoes for Orphan Souls project ... encourage support for Air1 and while also providing new shoes ...
(Date:10/19/2014)... Hastings and Hastings, a Phoenix personal ... throughout the greater Phoenix area and across Arizona reports ... to catastrophic automobile accidents. Statistics have indicated a steady ... Arizona. As such, Hastings and Hastings has seen a ... those who have been injured through no fault of ...
(Date:10/19/2014)... Texas (PRWEB) October 20, 2014 ... development for Partial Seizure, complete with comparative analysis ... mechanism of action (MoA), route of administration (RoA) ... featured news and press releases. It also reviews ... Partial Seizure and special features on late-stage and ...
(Date:10/19/2014)... SweetDressy.com, a professional company of women’s dresses and ... evening dresses . All the company’s old and ... discount is up to 66 percent off. , ... fashion field. Its dress specialists are striving to make ... of the world. All the company’s items are unique, ...
Breaking Medicine News(10 mins):Health News:KromaTiD Launches Genome Screening and Discovery Services 2Health News:KromaTiD Launches Genome Screening and Discovery Services 3Health News:Buckner Shoes for Orphan Souls® Garners Support from Air1 Radio 2Health News:Buckner Shoes for Orphan Souls® Garners Support from Air1 Radio 3Health News:Hastings And Hastings Reports Record Demand In 2014 For Legal Representation With Regard To Catastrophic Automobile Accidents 2Health News:Hastings And Hastings Reports Record Demand In 2014 For Legal Representation With Regard To Catastrophic Automobile Accidents 3Health News:Partial Seizure Therapeutic Pipeline Market Review H2 2014 in a New Report Available at RnRMarketResearch.com 2Health News:Partial Seizure Therapeutic Pipeline Market Review H2 2014 in a New Report Available at RnRMarketResearch.com 3Health News:Partial Seizure Therapeutic Pipeline Market Review H2 2014 in a New Report Available at RnRMarketResearch.com 4Health News:Promotion For Beautiful Long Evening Dresses Launched By SweetDressy.com 2
... SEATTLE Do genetic variations in DNA determine the ... to treat blood cancers and predict complications? The National ... of Health has awarded a $4.3 million, four-year grant ... out., John Hansen, M.D., a member of the Hutchinson ...
... , WEDNESDAY, Jan. 19 (HealthDay News) -- Taking kudzu root ... ethanol levels, which might lessen the desire for more alcohol, ... been used to reduce, but not stop, alcohol consumption and ... Examining this ancient remedy, scientists from Harvard Medical School ...
... Cancer scientists led by Dr. John Dick at the ... Children,s Research Hospital (Memphis) have found that defective genes ... organized in a more complex way than previously thought. ... (DOI:10.1038/nature09733), challenge the conventional scientific view that cancer ...
... By Amanda Gardner HealthDay Reporter , TUESDAY, ... to identify which people with stage II colon cancer face ... would be a huge help to doctors in determining which ... not, and it would be an improvement on existing ways ...
... 19 (HealthDay News) -- More than 40 percent of cancer ... and female patients, finds a new study. Researchers at ... cancer survivors and found that 43 percent had experienced pain ... at least two years later. Among white patients, ...
... APS announces Physical Review X (PRX), an online, ... of physics. As broad in scope as physics itself, ... advances physics and will be of value to the global ... peer review, and an open access venue in accord with ...
Cached Medicine News:Health News:Does our DNA determine how well we respond to stem-cell transplantation? 2Health News:New Clue to How Chinese Remedy Curbs Drinking 2Health News:Cancer scientists discover genetic diversity in leukemic propagating cells 2Health News:Cancer scientists discover genetic diversity in leukemic propagating cells 3Health News:Gene Test Might Predict Colon Cancer's Return 2Health News:Gene Test Might Predict Colon Cancer's Return 3Health News:1 in 5 Cancer Survivors Suffers Chronic Pain, Study Finds 2Health News:American Physical Society announces Physical Review X 2
All-silicone construction provides maximum softness and biocompatibility for enhanced patient comfort. Supplied sterile in peel-open packages. Intended for one-time use....
The 100% Silicone construction is ideal for pediatric and latex-sensitive patients....
BARDEX Red Rubber Urethral Catheter (Robinson Model)...
Used for injection into urethral strictures, bladder neck contracture, and the bladder wall. Supplied sterile in peel-open packages. Intended for one-time use....
Medicine Products: